Vasca
This article was originally published in The Gray Sheet
Executive Summary
FDA deems LifeSite hemodialysis access system revised labeling acceptable. Vasca reports receiving an Aug. 12 communication from the agency determining the firm's response to a November 2001 warning letter to be satisfactory. FDA originally requested that the Tewksbury, Massachusetts firm update labeling to reflect postmarket adverse event rates associated with off-label use of the device in unevaluated body sites and in certain patient populations (1"The Gray Sheet" Jan. 7, 2002, p. 9)...
You may also be interested in...
Vasca LifeSite Dialysis Product Labeling Changes Negotiated With FDA
Vasca, Inc. is in discussions with FDA to revise labeling for the LifeSite hemodialysis access system
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.